Street View: Strength in AbbVie's immunology pipeline to support revenue growth

** AbbVie ABBV.N slightly trimmed its 2026 profit forecast on Friday to account for its planned Apogee Therapeutics acquisition, while topping second-quarter estimates on strong immunology drug sales

** Canaccord Genuity ("buy," PT: $290) says AbbVie’s pipeline, an under-appreciated asset, is gaining momentum as key catalysts emerge that could support valuation gains

** RBC Capital Markets ("outperform," PT: $280) says sentiment is tied to immunology drug Skyrizi's ability to keep growing despite new competition and support from pipeline progress

** J.P.Morgan ("overweight," PT: $285) says co is among the "best positioned" in this space primarily as its immunology pipeline is improving visibility on revenue growth through the 2030s

** Morningstar (fair value: $200) says co's next-generation immunology drugs offer better efficacy and an improved side effect profile over Humira